Expertise in
23
conditions

Dr. Costas L. Constantinou

Hematology
UnityPoint Health Trinity Rock Island
2701 17th St, 
Rock Island, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
23
conditions
UnityPoint Health Trinity Rock Island
2701 17th St, 
Rock Island, IL 

Overview

Costas Constantinou is a Hematologist practicing medicine in Rock Island, Illinois.

Dr. Constantinou is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Lymphocytic Leukemia (CLL).

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 8 clinical trials. Dr. Constantinou is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in IL

Hospital Affiliations

Trinity Rock Island

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 15 Less Insurance Carriers -

Locations

UnityPoint Health Trinity Rock Island
2701 17th St, Rock Island, IL 61201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Integrated Cancer Repository for Cancer Research
Integrated Cancer Repository for Cancer Research
Enrollment Status: Recruiting
Publish Date: June 29, 2026
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Enrollment Status: Terminated
Publish Date: July 27, 2022
Intervention Type: Drug, Other
Study Drug: Varenicline
Study Phase: Phase 3
View 7 Less Clinical Trials

3 Total Publications

Effects of Montmorency tart cherry (Prunus Cerasus L.) consumption on vascular function in men with early hypertension.
Effects of Montmorency tart cherry (Prunus Cerasus L.) consumption on vascular function in men with early hypertension.
Journal: The American journal of clinical nutrition
Published: September 18, 2015
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

University Of Iowa Stead Family Children's Hospital

200 Hawkins Dr, 
Iowa City, IA 
 (52.0 miles away)
319-335-4958
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Tomasson is a Hematologist practicing medicine in Iowa City, Iowa. Dr. Tomasson is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Tomasson is currently accepting new patients.

Expertise in
22
conditions
Dr. Mario B. Sy
Hematology
Expertise in
22
conditions
Dr. Mario B. Sy
Hematology
Referral may be required

Hematology-Oncology Associates Of The Quad Cities PC

1351 Kimberly Rd Ste 100, 
Bettendorf, IA 
 (4.5 miles away)
563-355-7909
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients

Mario Sy is a Hematologist practicing medicine in Bettendorf, Iowa. Dr. Sy is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Richter Syndrome. Dr. Sy is currently accepting new patients.

Expertise in
16
conditions
Dr. Daniel J. Berg
Hematology | Oncology
Expertise in
16
conditions
Dr. Daniel J. Berg
Hematology | Oncology
Referral may be required

University Of Iowa Stead Family Children's Hospital

200 Hawkins Dr, 
Iowa City, IA 
 (52.0 miles away)
319-353-7800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Berg is a Hematologist and an Oncologist practicing medicine in Iowa City, Iowa. Dr. Berg is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Berg is currently accepting new patients.

Frequently Asked Questions about Dr. Costas L. Constantinou

How do I make an appointment with Dr. Costas L. Constantinou?

You can book an appointment with Dr. Costas L. Constantinou by calling their office at 309-779-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Costas L. Constantinou a top-rated expert for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Costas L. Constantinou is classified as an Distinguished expert for Monoclonal Gammopathy of Undetermined Significance (MGUS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Costas L. Constantinou specialize in?

While Dr. Costas L. Constantinou is a Hematology, they have specific expertise in Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Myelogenous Leukemia (CML), and Philadelphia-Negative Chronic Myeloid Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Costas L. Constantinou participate in research or clinical trials?

Yes. Dr. Costas L. Constantinou has published 3 articles and abstracts on conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS). You can view a list of Dr. Costas L. Constantinou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Costas L. Constantinou accept my insurance?

Dr. Costas L. Constantinou accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 309-779-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Constantinou's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile